Pharmaceuticals

GSK Shares Disappointment on Failure of its Lung Cancer Treatment in Phase III Trial

GSK Shares Disappointment on Failure of its Lung Cancer Treatment in Phase III T

GlaxoSmithKline Plc has reported that its experimental lung cancer treatment, MAGE-A3 antigen-specific cancer immunotherapeutic, failed in its phase III clinical trial to treat lung cancer. The company said that the drug failed in treating patients with non-small cell lung cancer (NSCLC) clinical trial.

Location: 
Person: 
Company: 

Intercept Liver Drug Registers Positive Data for POISE Trials

Intercept Liver Drug Registers Positive Data for POISE Trials

Experimental Live disease drug from Intercept Pharmaceuticals Inc has registered positive data in third late-stage trials. The company plans to file for FDA approval as the results from the international Phase three POISE drug trials make a strong case for the drug.

Britain to Follow Early-Access Medicine Scheme by April

Britain to Follow Early-Access Medicine Scheme by April

The government is planning to implement early-access to medicines scheme for increasing access to ground-breaking drugs for patients suffering serious condition. The government plans to launch the early access in April.

The government has taken initiative to help both the patients and pharmaceuticals companies, who are in urgent need of advanced medication. This scheme has already been implemented in the U.S. under ‘breakthrough medicines’ plan.

Person: 
Location: 

Nexavar, Bayer Drug Fails to Meet Primary Endpoint in Phase III Trial

Nexavar, Bayer Drug Fails to Meet Primary Endpoint in Phase III Trial

Bayer AG drug sorafenib (Nexavar) for treating patients with hepatocellular carcinoma (HCC) has failed in its Phase III trial to meet its primary endpoint in improving recurrence-free survival. Bayer Healthcare Pharmaceuticals Inc. and Onyx Pharmaceuticals Inc. have confirmed the results of the trial.

Jörg Möller, member of the Bayer HealthCare Executive Committee and Head of Global Development, said that the failure of the drug to meet its primary endpoint seems very disappointing.

Company: 

Pfizer Voluntarily Recalls 3 Lots of Effexor XR

Pfizer Voluntarily Recalls 3 Lots of Effexor XR

The U. S. Food and Drug Administration announced about Pfizer voluntarily recalling three lots of Effexor XR. The company has issued recall as the lots might have been contaminated with a heart drug and could lead to fatal consequences.

"Although Pfizer has not received any other such reports, these three lots are being voluntarily recalled as a precaution because they were packaged on the same line", said Pfizer.

Location: 
Company: 

Generic Lipitor Batches recalled by Indian Pharmaceutical major Ranbaxy

Generic Lipitor Batches recalled by Indian Pharmaceutical major Ranbaxy

Indian pharmaceutical major Ranbaxy Laboratories has recalled many batches of generic version of cholesterol drug Lipitor in the U.S. market. The company has faced tough U.S. FDA action over past few years due to quality issues. FDA has confirmed that Ranbaxy Labs has issued recall for more than 64,000 bottles of atorvastatin calcium tablets after they were found in wrong package of 10mg.

Location: 
Laboratories: 
Company: 

Novartis Blood Cancer Drug Jakavi Shows Positive Results in Phase III Trial

Novartis Blood Cancer Drug Jakavi Shows Positive Results in Phase III Trial

Novartis AG has informed successful final stage trial of blood cancer drug Jakavi (ruxolitinib). The Swiss pharmaceutical major said that the rare blood cancer drug has shown improvement in two key measures of disease control. Jakavi maintained red blood cell volume among study subjects. The drug worked without the requirement for phlebotomy.

The drug has been found effective in incurable blood cancer, Polycythemia vera, which currently has very limited treatment options. The selective JAK 1 / 2 inhibitor has provided encouraging results in Phase III trials.

Company: 

GSK 722LA could be Game Changer in HIV Prevention Efforts, Say Researchers

GSK 722LA could be Game Changer in HIV Prevention Efforts, Say Researchers

An experimental drug GSK 744LA could prove successful in treating repeated intrarectal infections with the deadly SHIV virus in monkeys, may also be used to protect AIDS infection in humans for three months, said US researchers. David Ho, researcher at the Aaron Diamond AIDS Research Center in New York, said that the drug could be maintained for three to four months in humans at adequate levels to keep the safe against infection.

Company: 

Ascendis Health Posts Impressive Results; Stock Price Jumps

Ascendis Health Posts Impressive Results; Stock Price Jumps

Ascendis Health posted impressive numbers and the stock was trading with more than 7 percent gains. The company posted 114 percent increase in revenue and 365 percent increase in net profit. The operation margin improved to 13 percent compared to 6 percent during last report.

The recently listed company reported revenue of R662 million and operating profit of R88 million. The stock listed on Johannesburg stock market on November 22, 2013 has rewarded the shareholders. The company has acquired stake in two companies and this has helped the revenue.

Location: 
Company: 

FDA announcement boosts Oxygen Biotherapeutics

FDA announcement boosts Oxygen Biotherapeutics

U.S. Food and Drug Administration has lifted a clinical hold on an experimental brain injury drug developed by Oxygen Biotherapeutics. After the announcement, the stock price of Oxygen Biotherapeutics jumped more than 30 percent.

Location: 

Pages

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More

Tesla announces risky new approach to customer service

During the past few years, Tesla was slammed by a... Read More